Fluticasone and Vilanterol
- Generic Name
- Fluticasone and Vilanterol
Overview
No overview information available.
Background
No background information available.
Indication
⑴哮喘：本品适用于成人哮喘患者的维持治疗，其中包括规律吸入糖皮质激素，并“按需”吸入短效β2-受体激动剂治疗控制不佳的成人哮喘患者。⑵慢性阻塞性肺病（COPD）：本品100μg/25μg适用于吸入支气管扩张剂后FEV1占正常预计值百分比<70%，且规律应用支气管扩张剂治疗情况下，仍有急性加重史的成人COPD患者的维持治疗。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Approved Products
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|
No FDA products found
No FDA products found for this drug
EMA Approved Products
Product Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
HSA Approved Products
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval Number |
|---|
No HSA products found
No HSA products found for this drug
NMPA Approved Products
Product Name | Approval Number | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|---|---|---|---|---|---|---|---|---|
国药准字HJ20180044 | 吸入制剂 | N/A | 每泡含糠酸氟替卡松100μg与三苯乙酸维兰特罗25μg（按C₂₄H₃₃Cl₂NO₅计），递送剂量为糠酸氟替卡松92μg与三苯乙酸维兰特罗22μg（按C₂₄H₃₃Cl₂NO₅计） | Chemical Drug | Approved | 2023/06/07 | Import | ||
国药准字HJ20180045 | 吸入制剂 | N/A | 每泡含糠酸氟替卡松200μg与三苯乙酸维兰特罗25μg（按C₂₄H₃₃Cl₂NO₅计），递送剂量为糠酸氟替卡松184μg与三苯乙酸维兰特罗22μg（按C₂₄H₃₃Cl₂NO₅计） | Chemical Drug | Approved | 2023/06/07 | Import |
PPB Approved Products
Product Name | Registration Code | Company | Category | Sale Type | Registration Date |
|---|
No PPB products found
No PPB products found for this drug
TGA Approved Products
Product Name | ARTG ID | Sponsor | Status | Registration Date | Ingredient |
|---|
No TGA products found
No TGA products found for this drug
© Copyright 2025. All Rights Reserved by MedPath